Payment overview · 2025
General Payments
$295.26
13 reported records · 10 companies
Healthcare provider profile · identity verified
Gregory T Levickas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CATONSVILLE, MD · NPI 1891739744
Verified facts
What the public records show
CMS Open Payments records show Gregory T Levickas, MD received $295.26 in general payments during 2025 across 13 reported records.
Exact Sciences Corporation accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.80 | 24.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.08 | 13.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.81 | 11.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.20 | 10.6% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $22.46 | 7.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.45 | 7.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.76 | 7.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.02 | 6.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.22 | 6.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.46 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $295.26 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $71.80 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
175 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 776 | 228 |
| Amlodipine Besylate | Amlodipine Besylate | 503 | 143 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 72 |
| Losartan Potassium | Losartan Potassium | 219 | 60 |
| Lisinopril | Lisinopril | 208 | 61 |
| Ozempic | Semaglutide | 175 | 27 |
| Eliquis | Apixaban | 166 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 48 |
| Valsartan | Valsartan | 159 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 41 |
| Gabapentin | Gabapentin | 156 | 39 |
| Mirtazapine | Mirtazapine | 156 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 155 | 36 |
| Meloxicam | Meloxicam | 134 | 47 |
| Trazodone Hcl | Trazodone Hcl | 129 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 37 |
| Tramadol Hcl | Tramadol Hcl | 123 | 30 |
| Furosemide | Furosemide | 120 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 35 |
| Potassium Chloride | Potassium Chloride | 119 | 32 |
| Carvedilol | Carvedilol | 112 | 34 |
| Simvastatin | Simvastatin | 111 | 31 |
| Clonazepam | Clonazepam | 106 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 37 |
| Metformin Hcl Er | Metformin Hcl | 103 | 37 |
| Metformin Hcl | Metformin Hcl | 102 | 34 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 94 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 92 | 29 |
| Sertraline Hcl | Sertraline Hcl | 90 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 25 |
| Omeprazole | Omeprazole | 87 | 22 |
| Spironolactone | Spironolactone | 86 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 11 |
| Jardiance | Empagliflozin | 80 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 22 |
| Pregabalin | Pregabalin | 72 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 21 |
| Glipizide | Glipizide | 70 | 18 |
| Montelukast Sodium | Montelukast Sodium | 68 | 20 |
| Famotidine | Famotidine | 67 | 23 |
| Bupropion Xl | Bupropion Hcl | 65 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 18 |
| Lorazepam | Lorazepam | 63 | 17 |
| Farxiga | Dapagliflozin Propanediol | 62 | 15 |
| Ibuprofen | Ibuprofen | 56 | 13 |
| Buspirone Hcl | Buspirone Hcl | 55 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 55 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 19 |
| Alprazolam | Alprazolam | 52 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | 15 |
| Allopurinol | Allopurinol | 49 | 17 |
| Atenolol | Atenolol | 48 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | 11 |
| Glimepiride | Glimepiride | 46 | 16 |
| Azithromycin | Azithromycin | 45 | 39 |
| Valacyclovir | Valacyclovir Hcl | 45 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Ezetimibe | Ezetimibe | 43 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 17 |
| Prednisone | Prednisone | 42 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 14 |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 38 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 30 |
| Telmisartan | Telmisartan | 38 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 32 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 14 |
| Chlorthalidone | Chlorthalidone | 35 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 18 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | 13 |
| Nabumetone | Nabumetone | 32 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $295.26 · 13 records | Exact Sciences Corporation | BREZTRI, CAMZYOS, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, LINZESS, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, Senza, UBRELVY, Veozah | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error